Skip to main content

Table 3 Patient characteristics of the study population

From: A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

Pt

Age

Gender

PS

Stage at diagnosis

Prevaccination therapy

Extent of disease at first vaccination

1

61

M

1

II

SX2

Lung and mediastinal LN metastasis

2

66

F

0

III

SX2

NED

3

40

M

0

III

SX3, IFN-α, IL-2

NED

4

71

M

1

IV

SX1, IFN-α

Lung and abdominal wall metastasis

5

65

M

1

III

SX2, IL-2, RX1

NED

6

69

M

0

III

SX4, RFAX2

Lung and liver metastasis

  1. Abbreviations: Pt = patient; PS = performance status; NED = no evidence of disease; M = male; F = female; LN = lymph nodes; S = surgery; IFN-α = Interferon-α; IL-2 = Interleukin-2; Rx = radiation; RFA = radiofrequency ablation.